David Williams - Merck Ex Officer
| MRK Stock | MXN 2,115 18.00 0.86% |
Insider
David Williams is Ex Officer of Merck Company
| Age | 54 |
| Phone | 908 740 4000 |
| Web | https://www.merck.com |
David Williams Latest Insider Activity
Tracking and analyzing the buying and selling activities of David Williams against Merck stock is an integral part of due diligence when investing in Merck. David Williams insider activity provides valuable insight into whether Merck is net buyers or sellers over its current business cycle. Note, Merck insiders must abide by specific rules, including filing SEC forms every time they buy or sell Merck'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
David Williams over six months ago Bona fide gift to David Williams of 377 shares of NACCO Industries subject to Section 16 | ||
David Williams over a year ago NACCO Industries exotic insider transaction detected | ||
David Williams over a year ago Bona fide gift to David Williams of 207 shares of NACCO Industries subject to Section 16 | ||
David Williams over a year ago Acquisition by David Williams of 5457 shares of Regis subject to Rule 16b-3 |
Merck Management Efficiency
The company has return on total asset (ROA) of 0.1268 % which means that it generated a profit of $0.1268 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.351 %, meaning that it generated $0.351 on every $100 dollars invested by stockholders. Merck's management efficiency ratios could be used to measure how well Merck manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Donald Zakrowski | Eli Lilly and | N/A | |
| Diogo Rau | Eli Lilly and | N/A | |
| David MD | Amgen Inc | 60 | |
| Johannes MD | Roche Holding AG | 66 | |
| Linda Higgins | Gilead Sciences | 61 | |
| Michael CPA | Biogen Inc | 59 | |
| Timothy Power | Bristol Myers Squibb | N/A | |
| Cari Gallman | Bristol Myers Squibb | N/A | |
| Michael Quigley | Gilead Sciences | N/A | |
| Jitendra Tyagi | Bristol Myers Squibb | N/A | |
| Diane Wilfong | Gilead Sciences | 61 | |
| Nicole Murphy | Biogen Inc | N/A | |
| Christopher Viehbacher | Biogen Inc | 63 | |
| Martin MIBS | Eli Lilly and | 60 | |
| Alonzo Weems | Eli Lilly and | N/A | |
| Jacquie CFA | Gilead Sciences | N/A | |
| Peter Griffith | Amgen Inc | 64 | |
| Barbara Schadler | Roche Holding AG | 61 | |
| Thomas Schinecker | Roche Holding AG | 48 | |
| Sandra Esq | Bristol Myers Squibb | 62 | |
| Susan Esq | Biogen Inc | 66 | |
Management Performance
| Return On Equity | 0.35 | |||
| Return On Asset | 0.13 |
Merck Company Leadership Team
Elected by the shareholders, the Merck's board of directors comprises two types of representatives: Merck inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck's management team and ensure that shareholders' interests are well served. Merck's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Cristal Downing, Ex Officer | ||
| Jennifer Zachary, General Counsel | ||
| David Williams, Ex Officer | ||
| Caroline Litchfield, Ex CFO | ||
| Lisa LeCointeCephas, VP Officer | ||
| Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health | ||
| Kenneth Frazier, Chairman, CEO and Pres | ||
| Peter Dannenbaum, VP Relations | ||
| Jennifer Mauer, VP Communications | ||
| Robert JD, Pres Chairman |
Merck Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.35 | |||
| Return On Asset | 0.13 | |||
| Profit Margin | 0.24 % | |||
| Operating Margin | 0.38 % | |||
| Current Valuation | 5.9 T | |||
| Shares Outstanding | 2.54 B | |||
| Shares Owned By Insiders | 0.10 % | |||
| Shares Owned By Institutions | 76.37 % | |||
| Price To Earning | 469.71 X | |||
| Price To Book | 6.28 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Merck Stock Analysis
When running Merck's price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.